Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention
The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.
Diagnosis & Disease Information
Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma
Patients had similar HRQOL scores by all measures at baseline, but experienced significant changes in scores for the HRQOL domains of Body Image, Diarrhea, Nutrition, Pain, and Role Function.
Eryaspase May Prolong Overall and Progression-free Survival in Pancreatic Cancer
Researchers randomly assigned 140 patients with metastatic pancreatic cancer to receive eryaspase with standard of care FOLFOX or chemotherapy alone.
Survival Benefit With Pembrolizumab Confirmed in Urothelial Carcinoma
The KEYNOTE-045 trial randomly assigned 542 patients with UC who progressed after 2 or fewer prior therapies to receive pembrolizumab or investigator’s choice of paclitaxel, docetaxel, or vinflunine.
Liquid Biopsies Are Highly Sensitive for Actionable Mutations in Solid Tumors
Alterations conferring resistance to targeted agents were identified among 18% of samples from NSCLC, breast, colorectal, and prostate cancers, melanoma, and gastrointestinal stromal tumors.
No Difference in Survival With CT Scan at Follow-ups for Resected NSCLC
Although these data did not demonstrate improved survival with the inclusion of a CT scan at routine follow-up visits, the authors noted that a longer follow-up time is necessary to identify any long-term OS benefits.
Durvalumab May Prolong PFS in Non-small Cell Lung Cancer After Chemoradiation
Researchers randomly assigned 713 patients with NSCLC who did not progress after 2 or more cycles of platinum-based concurrent chemoradiation therapy to receive durvalumab 10 mg/kg consolidation therapy or placebo for up to 12 months.
Initial Abemaciclib Improves PFS and ORR in Advanced Breast Cancer
Researchers compared the efficacy of abemaciclib plus anastrozole or letrozole vs placebo plus anastrozole or letrozole among patients not previously treated with a systemic therapy.
TILs May Predict Pembrolizumab Response in Triple-negative Breast Cancer
The results of the study demonstrate that increased TIL levels may be associated with a greater response to pembrolizumab monotherapy in patients with mTNBC, especially in the first-line setting.
Osimertinib Shows Promise As A First-line Therapy in EGFRm NSCLC
Patients who received osimertinib had a PFS of 18.9 months compared with 10.2 months among those who received SoC treatments (P < .0001).
- Loading...
Loading...
Next post in ESMO 2017
Loading... 
Loading...